Drug information of Travoprost

Prostaglandin F2-alpha analog; increasing outflow of aqueous humor

A selective FP prostanoid receptor agonist which lowers intraocular pressure by increasing trabecular meshwork and outflow

Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analog that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid . The travoprost free acid is potent and highly selective for the FP prostanoid receptor

Absorption: through the cornea

Peak Plasma Time: within 30 min

Metabolism: hydrolyzed by esterases in the cornea

Excretion: urinary; complete systemic elimination within 1 hr

Onset of Action:~2 hours;

 Peak effect: 12 hours

Half-Life Elimination:45 minute

Absorption: through the cornea

Peak Plasma Time: within 30 min

Metabolism: hydrolyzed by esterases in the cornea

Excretion: urinary; complete systemic elimination within 1 hr

Onset of Action:~2 hours;

 Peak effect: 12 hours

Half-Life Elimination:45 minute

Ocular hypertension/glaucoma (open-angle)

Instill 1 drop into affected eye(s) once daily in the evening

Hypersensitivity

Pregnancy

Increased pigmentation of iris & periorbital tissue & increased pigmentation, thickening, elongation & growth of eyelashes

Ocular hyperemia

Decreased visual acuity

Ocular discomfort

Foreign body sensation

Pain

Pruritus

Abnormal vision

Blepharitis

Blurred vision

Cataract

Conjunctivitis

Dry eye

Iris discoloration

Keratitis

Lid margin crusting

Photophobia

Subconjunctival hemorrhage

Tearing

Prostaglandin analogs reported to cause periorbital and lid changes including deepening of the eyelid sulcus

Bimatoprost-latanoprost-latanoprostene bunod ophthalmic-tafluprost-unoprostone ophthalmic-aspirin-aspirin rectal-bromfenac ophthalmic-celecoxib-choline magnesium trisalicylate-diclofenac-diclofenac ophthalmic-diflunisal-etodolac-fenoprofen-flurbiprofen-flurbiprofen ophthalmic-ibuprofen-ibuprofen IV-ibuprofen/famotidine-indomethacin-ketoprofen-ketorolac-ketorolac intranasal-ketorolac ophthalmic-meclofenamate-mefenamic acid-meloxicam-nabumetone-naproxen-nepafenac ophthalmic-oxaprozin-piroxicam-salsalate-sulindac-tolmetin

-Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis

-Eye color changes

-Intraocular inflammation and exacerbation of inflammation may occur

-Topical prostaglandin analogues have been associated with the occurrence/exacerbation of macular edema

-Use with caution in patients with a history of herpes simplex keratitis; reactivation may occur. Avoid use in patients with active herpes simplex keratitis

-Use cautiously in patients with intraocular inflammation as topical prostaglandins may worsen inflammation

-Use in pediatric patients (<16 years of age) is not recommended by the manufacturer due to possible safety issues of increased pigmentation following long-term chronic use

- Remove contact lens prior to instillation

-Wash your hands before using the eye drops.

-tell your doctor if you have ever had:

• swelling or an infection in your eye;
• retinal detachment;
• eye surgery or injury affecting the lens of your eye.

Animal studies have shown teratogenic results. There are no adequate and well-controlled studies in pregnant women.

Ophthalmic prostaglandins, such as travoprost, are generally avoided during pregnancy due to a theoretical risk of miscarriage and premature labor